Skip to main content
. Author manuscript; available in PMC: 2019 Mar 15.
Published in final edited form as: Clin Cancer Res. 2018 Feb 1;24(10):2395–2407. doi: 10.1158/1078-0432.CCR-17-1594

Figure 5. HSF1 pathway inhibition decreases viability of patient-derived myeloma cells whilst sparing human PBMCs and a bone marrow stromal cell line.

Figure 5

Cell viability of Annexin V-APC and PI stained (A) CD138+ primary myeloma cells from 5 patients, (B) human RPMI-8226 cell line and PBMCs from healthy donor, (C) RPMI-8226 and the bone marrow stromal cell line (HS-5) were assessed by flow cytometry following 48 hour treatment with CCT251236 or KRIBB11. Graphs represent the population of Annexin V-APC negative and PI negative cells as a percentage of vehicle-treated controls (Veh). Data are shown as means ±S.E.M. of three independent experiments. Significant differences were calculated by Student’s t-tests and P-values are indicated where * ≤ 0.05, ** ≤ 0.01 and *** ≤ 0.001 comparing RPMI-8226 with PBMC or HS-5 cell viability at the same compound concentration.